Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.57 | N/A | +2.13% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $6.57 | N/A | +2.13% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about future growth. They acknowledged current market pressures but remain focused on strategic initiatives.
Management highlighted strong performance in key segments despite economic challenges.
They emphasized ongoing investments in innovation and customer engagement.
Thermo Fisher Scientific's earnings report shows a positive surprise in EPS, indicating stronger profitability than expected. However, the stock fell by 2.61% in reaction, likely due to the lack of revenue data and guidance. Investors may be concerned about the absence of future outlook, which could affect confidence going forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BERKLEY W R CORP
Jan 26, 2026